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The resultsof comparative trials of fluoroquinolones for the treatment of uncomplicated
and complicated urinary tract infections (UTI) were reviewed. Severalrandomized, com-
parative trials showedthat in uncomplicated UTI norfloxacin, ciprofloxacin, and ofloxa-
cin wereat least as effectiveas trimethoprim-sulfamethoxazole (TMP-SMZ) and amox-
icillinand usually more effectivethan nalidixicacid, pipemidicacid, and nitrofurantoin.
Comparativetrials of single-dose regimens have, however, beenlimited. A few randomized,
comparative trials have shown that in complicated UTI norfloxacin, ciprofloxacin, and
ofloxacin wereat least as effectiveas amoxicillinand TMP-SMZand usually more effec-
tive than pipemidic acid. Moreover, preliminary results indicate that fluoroquinolones
might be effectivefor the oral treatment of complicated UTI that are difficult to treat,
especially those due to Pseudomonas aeruginosa. Comparative trials are neededto estab-
lish the value of fluoroquinolones for chronic bacterial prostatitis. There are no conclu-
sivedata on fluoroquinolone treatment of UTI in patients with renal failure. Emergence
of resistantpathogensduring therapywith fluoroquinolones has beeninfrequentbut might
be more frequent in complicated UTI caused by P. aeruginosa.
Although highly effective and well-established an-
tibiotic regimens are available for the treatment of
urinary tract infection (UTI), there is a need for new
antimicrobial agents, especially for the treatment of
outpatients with UTI that are difficult to treat and
for which most of the drugs available for oral treat-
ment are ineffective.
The fluoroquinolones have several properties that
suggest their potential clinical utility for the treat-
ment of UTI, including high activity in vitro against
virtually all urinary tract pathogens and good ab-
sorption after oral administration that results in
prolonged high levels of drug in urine [1].
The methodologic problems associated with open
and comparative trials evaluating the efficacy of new
antibiotics for the treatment of UTI have recently
been reviewed [2]. For this review of the efficacy of
fluoroquinolones for the treatment of UTI, we have
emphasized those studies that have both sufficient
data for a clear classification of UTI and data on
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follow-up urine cultures 4-6 weeks after the end of
treatment (unless otherwise mentioned). In this
evaluation, bacteriologic cure (sterile urine) was con-
sidered as the end point of antibiotic treatment since
the definitions of clinical response, when stated, var-
ied from one study to another and symptoms may
disappear in the absence of bacteriologic cure. In ta-
ble 1, which outlines the efficacy of fluoroquinolone
treatment of UTI by infecting organism, only data
from studies (noncomparative and comparative) that
provided sufficient information to permit a clear
classification of UTI were taken into account. We
will consider and analyze separately the uncompli-
cated and the complicated UTI.
Uncomplicated UTI is an infection occurring in
a patient without anatomic or functional abnormal-
ities of the urinary tract. Such infections are amena-
ble to either a single dose or to very short-term treat-
ment [3-5]. In contrast, complicated UTI will be
considered as those that occur during pregnancy or
in patients with anatomic or functional abnormali-
ties of the urinary tract, those in patients with de-
bilitating underlying diseases such as diabetes mel-
litus, or those in patients presenting with the clinical
picture of acute pyelonephritis. The treatment of
complicated UTI should be more prolonged than
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Table 1. Rates of eradication of organisms after fluoroquinolone treatment of urinary tract infections (UTI).
Percentage of strains eradicated after treatment (total no. isolated before treatment)*
Coagulase-
Type of infection, negative Escherichia Proteus Klebsiella Pseudomonas Enterobacter
fluoroquinolone staphylococci Enterococci coli species species aeruginosa species
Uncomplicated UTI
Norfloxacin 94 (32) 93 (228) 100 (17) 58 (12) 100 (8) 100 (5)
Ciprofloxacin 87 (15) 100 (7) 96 (266) 100 (10) 100 (6)
Ofloxacin 100 (8) 94 (97) 94 (18) 100 (8)
Enoxacin 99 (107)
Pefloxacin 88 (48) 100 (5) 100 (5)
Complicated UTI
Norfloxacin 100 (5) 96 (27) 81 (36)
Ciprofloxacin 100 (5) 100 (5) 98 (93) 100 (35) 85 (27) 54 (112) 100 (10)
Ofloxacin 89 (19) 94 (36) 94 (65) 93 (29) 78 (27) 67 (52) 75 (8)
Enoxacin 100 (22) 75 (12) 79 (38)
Pefloxacin 100 (5) 95 (62) 95 (20) 100 (6)
NafE. Data are from [10-53] and from data on file, Laboratoire Roger Bellon (Neuilly-sur-Seine, France).
* The minimum number of strains required to be reported in this table was five. The total number of strains isolated before
treatment was calculated by summarizing the data from all trials that used one of the fluoroquinolones for the treatment of uncompli-
cated or complicated UTI. Eradication rates (070) were the number of isolates of one bacterial species eradicated at follow-up divided
by the total number of isolates of the same species found before treatment.
that of uncomplicated UTI since relapses frequently
occur after short-term treatment [4] and even after
courses of therapy longer than 10-14 days [5, 6].
There are suggestions that 6 weeksof antibiotic ther-
apy may be needed to eradicate complicated (relaps-
ing) infections, as shown in women with upper UTI
[7], in renal transplant recipients [8], and in men with
recurrent UTI [9].
Because the treatment of both uncomplicated and
complicated UTI are relatively wellstandardized and
because most antibacterial agents that achieve rea-
sonable antibacterial activity in the urine are effec-
tive for the treatment of UTI, it is not surprising that
the new quinolones have shown good activity in
open, noncomparative studies. Even placebo ther-
apy might achieve a cure rate of up to 50010 in fe-
male patients with acute symptomatic UTI. Thus,
this review will consider only those studies that have
compared in a prospective, randomized fashion
fluoroquinolone therapy with well-established regi-
mens. In addition, we will also consider those studies
that have tested in a prospective way various dosages
or durations of treatment of fluoroquinolones. Fi-
nally, this reviewwill analyze the results of open trials
specifically aimed at treating UTI caused by Pseu-
domonasaeruginosa, for which no alternative orally
administrable drugs are presently available.
Efficacy of Fluoroquinolone Treatment of UTI,
by Organisms
Table 1summarizes the data on the rates of eradica-
tion of different organisms from the urinary tract
after treatment with five fluoroquinolones. Obvi-
ously, a precise comparison of the eradication rate
for one drug with that for another was not possible
since the duration of treatment varied considerably
from one study to another. Furthermore, although
in the majority of studies, follow-up cultures were
performed 4-6 weeks after the end of treatment, in
some studies such cultures were done as early as 7-9
days after completion of therapy. Finally, only a
small number of UTI due to gram-positive organ-
isms were included in these studies, since all studies
excluded strains resistant in vitro, a common pat-
tern, especially among enterococci tested against
fluoroquinolones.
Randomized Trials with Fluoroquinolones for the
Treatment of Uncomplicated UTI
Trials aimed at defining optimal treatment regi-
mens. Rugendorff and Schneider [54] treated 59
women with acute infections with either a single dose
of norfloxacin (800 mg) or a 3-day course (800 mg
Fluoroquinolones for UTI
daily) and reported a slightly, but not significantly,
better cure rate after the 3-day regimen (93.7070) than
after the single dose (85.2070).
Graeff et al. [55] reported that a 3-day course of
ciprofloxacin (200 mg daily) was not significantly
superior to a single dose (250 mg) for the treatment
of postoperative UTI in 100 gynecologic patients.
Garlando et al. [25] recently studied two single-dose
regimens of ciprofloxacin (either 100 mg or 250 mg
orally) for the treatment of acute UTI in 38 women.
The cure rates in the two groups (89% and 84%,
respectively) were similar, but two of four episodes
due to Staphylococcus saprophyticus, as compared
with only three of 34 due to gram-negative En-
terobacteriaceae, could not be cured. The rate of kill-
ing by ciprofloxacin of S. saprophyticus in vitro was
significantly slower than that of four strains of Esch-
erichia coli.
Ludwig [46] treated 43 patients with either a 1-
day course (200 mg) or a 3-day course of ofloxacin
and reported similar cure rates (91 % and 95%) for
the two regimens.
Randomized, comparative trials. The results of
randomized, comparative trials are summarized in
table 2. Norfloxacin was compared with trimetho-
prim-sulfamethoxazole (TMP-SMZ) in several ran-
domized, comparative trials for the treatment of un-
complicated UTI [10-17, 56, 59]. In each trial,
norfloxacin was at least as effective as TMP-SMZ.
In a large trial including 323 patients, norfloxacin
(800 mg daily for 3-10 days) was significantly more
effective (97070 cure rate) than TMP-SMZ (90070 cure
rate) [59]. In the largest randomized, double-blind
multicenter study, which included more than 600 pa-
tients, two norfloxacin regimens (400 or 800 mg
daily) werecompared with TMP-SMZ (320/1,600 mg
daily) given for 7 days [60]. A minority of the pa-
tients had recurrent UTI «(\)25%) or UTI compli-
cated by factors such as structural abnormalities of
the urinary tract, stones, or diabetes mellitus
«(\)15%). The bacteriologic efficacy 4 weeks after the
end of treatment was similar in all treatment groups
(88%-89070). However, the lower dose of norfloxa-
cin (400 mg) was less effective than the higher dose
(800 mg) and than TMP-SMZ for UTI in men and
for patients with complicated UTI.
Among those trials that determined bacterial sus-
ceptibilities after norfloxacin therapy [10-13, 15-17],
only one therapeutic failure was due to superinfec-
tion with a resistant group B streptococcal strain [16].
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One study compared a single dose of norfloxacin
(1,200mg) to a single dose of TMP-SMZ (480/2,400
mg) for the treatment of uncomplicated UTI in 43
women: the cure rates were similar (88070 and 82%,
respectively) [17]. The two failures (relapses) after
norfloxacin therapy were due to strains of S. sapro-
phyticus (that were still susceptible to norfloxacin
in vitro). When norfloxacin was compared with nali-
dixic acid and pipemidic acid, norfloxacin was sig-
nificantly more effective [18,61]. Finally, norfloxa-
cin was slightly, but not significantly, more effective
than amoxicillin for the treatment of uncomplicated
UTI in geriatric patients [62].
Henry et al. [36] treated 65 women in a prospec-
tive, randomized, double-blind study with either
ciprofloxacin (500 mg daily) or TMP-SMZ (3201
1,600mg daily) for 10days. They reported a slightly
better cure rate after ciprofloxacin (100070) than af-
ter TMP-SMZ (94070) therapy. Moreover, ciproflox-
acin was significantly less toxic. Newsom et al. [38]
reported a higher cure rate after a 5-day course of
ciprofloxacin (200 mg daily) than after trimethoprim
alone (400 mg daily) in 32 geriatric patients with un-
complicated UTI. In one study of 75 hospital inpa-
tients (50% with complicated UTI), two ciprofloxa-
cin regimens (200 mg and 500 mg daily) given during
5 days were compared with TMP-SMZ (320/1,600
mg daily) [37]. Only the two ciprofloxacin groups
included patients with infections due to P. aerugi-
nosaor Acinetobacter species. In spite of this, both
ciprofloxacin regimens were at least as effective as
TMP-SMZ. In a further study of 60 patients with
uncomplicated and complicated UTI, ciprofloxacin
(500 mg daily) was significantly superior to TMP-
SMZ (320/1,600 mg daily) given for 7-10 days [63].
In a limited study, ciprofloxacin appeared more ef-
fective than nalidixic acid [26].
Several randomized, comparative studies of oflox-
acin (usually given for 3-5 days) for the treatment
of uncomplicated UTI were performed in Europe
[64]. Overall, ofloxacin had an efficacy similar to
that of TMP-SMZ. Similarly, one study from the
United States compared two regimens of ofloxacin
(400 mg and 600 mg daily) to TMP-SMZ (320/1,600)
given for 7 days to 39 women with uncomplicated
UTI. Bacteriologic cure was achieved in all patients
[65]. Ofloxacin was more effective than nitrofuran-
toin for the treatment of uncomplicated UTI in two
studies [66, 67]. When compared with pipemidic
acid, ofloxacin was significantly more effective, but
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Table 2. Results of randomized comparative trials of fluoroquinolones for the treatment of uncomplicated urinary
tract infections.
No. of Dosage Duration Bacteriologic
Agents patients (mg/day) (days) cure rate (070) Reference(s)
Norfloxacin 800· 75-100
vs. 816 lOt 10-17, 56-59
Trimethoprim-sulfamethoxazole
(TMP-SMZ) 320/1,600 70-100
Norfloxacin 800 96
vs. 110 3 18
Nalidixic acid 1,980 82
Norfloxacin 800 91
vs. 197 10 61
Pipemidic acid 750 79
Norfloxacin 800 83
vs. 91 7 62
Amoxicillin 750 74
Ciprofloxacin 500 100
vs. 65 10 36
TMP-SMZ 320/1,600 94
Ciprofloxacin 200 94
vs. 32 5 38
TMP 400 60
Ciprofloxacin 200 71
vs. 19 7 26
Nalidixic acid 2,000 33
Ofloxacin 100 81
vs. 72 3-5 64
TMP-SMZ 320/1,600 80
Ofloxacin 100 3-5 94
vs. 189 64
Nalidixic acid 4,000 7 77
Ofloxacin 200 3 78/91
vs. 123 66,67
Nitrofurantoin 300 7 66/77
Ofloxacin 200 3 81
vs. 50 43
Pipemidic acid 800 5 55
Enoxacin 300 99
vs. 252 7 52
Pipemidic acid 750 90
• In two studies [11, 56] the daily dose was 400 mg; one study [17] compared a single dose of norfloxacin (1,200 mg) and TMP-
SMZ (48012,400 mg).
t Duration of treatment was 10 days in seven of 12 trials [10-14, 56, 58], 7-10 days in two trials [15, 16], 7 days in one trial
[57], 3-10 days in one trial [59], and a single dose in one trial [17].
the follow-up period was short (l week) [43]. More- pipemidic acid for the treatment of acute uncompli-
over, ofloxacin was compared with nalidixic acid for cated cystitis in women and observed a significantly
the treatment of uncomplicated UTI and achieved higher cure rate with enoxacin, but no follow-up cul-
a higher rate of cure [64]. tures were performed. In conclusion, fluoroquino-
Kamidono et al. [52] compared enoxacin with lones were at least as effective as other well-
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Table 3. Results of randomized comparative trials of fluoroquinolones for the treatment of complicated urinary
tract infections.
No. of Dosage Duration Bacteriologic
Agents patients (mg/day) (days) cure rate (OJo) Reference(s)
Norfloxacin 800 95
vs. 40 7 19
Amoxicillin 750 75
Norfloxacin 800 63/75
vs. 530 5 68,69
Pipemidic acid 2,000 48/62
Norfloxacin 800 93
vs. 109 28-42 70
Trimethoprim-sulfamethoxazole
(TMP-SMZ) 32011,600 80
Norfloxacin 800 100
vs. 28 14-42 24
Parenteral therapy (~-lactam
± aminoglycoside) 88
Ciprofloxacin 500 63
vs. 61 10 71
TMP-SMZ 320/1,600 45
Ciprofloxacin 200 (iv) 88
vs. 40 Not stated 72
Mezlocillin 4,000 57
Ofloxacin 400 82
vs. 425 7 64
TMP-SMZ 320/1,600 80
Ofloxacin 400 96
vs. 50 7 64
Amoxicillin + davulanic acid 1,875 57
Ofloxacin 600 89
vs. 228 5 42
Pipemidic acid 2,000 72
Enoxacin 600 89
vs. 393 5 52
Pipemidic acid 2,000 68
established antimicrobial agents, but in the majority
of the trials, the duration of therapy for uncompli-
cated UTI was too long.
Randomized, Comparative Trials for the
Treatment of Complicated UTI
The results of some randomized, comparative trials
of treatment of complicated UTI are summarized
in table 3. When norfloxacin was compared with
amoxicillin for the treatment of complicated UTI
in geriatric patients, it proved slightly, but not sig-
nificantly, better than amoxicillin (19]. Norfloxacin
was superior to pipemidic acid in two double-blind
randomized studies [68,69). However,in both studies
the follow-up period may have been inadequate. Sab-
baj et al. [70] treated 109 men with recurrent UTI
with either norfloxacin or TMP-SMZ for 4-6 weeks
and reported a significantly higher cure rate with nor-
floxacin. In an open, comparative study, 28 patients
with complicated UTI due to organisms resistant to
aminoglycosides and TMP-SMZ were treated orally
with norfloxacin or with a parenteral regimen (usu-
ally a 13-lactam plus an aminoglycoside) for 2-6
weeks [24]. Norfloxacin cured more patients (100070)
than did the parenteral regimens (88%), but the
follow-up period may have been inadequate for all
patients.
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Boerema et al. [71] compared ciprofloxacin with
TMP-SMZ for complicated UTI in male and female
patients with anatomic or functional disorders of the
urinary tract. Four to 6 weeks after therapy, the cure
rate among patients treated with ciprofloxacin was
higher (63%) than that among those treated with
TMP-SMZ (45010). Similarly, Peters [72] found a
higher cure rate 4 weeks after the end of therapy in
20 urologic patients treated iv with ciprofloxacin than
in patients treated with mezlocillin.
Ofloxacin was compared with TMP-SMZ in sev-
eral randomized studies of Europe for the treatment
of complicated UTI [64]. The cure rates reported for
the two regimens were similar. A smaller number of
patients were included in trials comparing ofloxa-
cin with a fixed combination of amoxicillin plus
clavulanic acid [64]. Bacteriologic cures were ob-
served in more patients treated with ofloxacin than
in those treated with amoxicillin plus clavulanic acid.
In a large double-blind trial in Japan that compared
ofloxacin with pipemidic acid for the treatment of
UTI complicated by factors such as neurogenic blad-
der dysfunction, lithiasis, obstruction, or neoplasms,
ofloxacin was significantly more effective than
pipemidic acid [42]. However, it is unclear in that
study when follow-up cultures were performed.
Enoxacin was compared with pipemidic acid for
the treatment of complicated UTI, and a signifi-
cantly higher cure rate was reported for patients
treated with enoxacin, but no follow-up cultures were
performed [52].
In conclusion, the new quinolones were at least
as effective as TMP-SMZ or amoxicillin for the treat-
ment of complicated UTI. In this setting, however,
in some trials the duration of therapy was clearly too
short and adequate follow-up cultures often were
missing.
Fluoroquinolones for the Treatment of UTI
Due to R aeruginosa
Leigh and Emmanuel [20] observed an 84% cure rate
in 19 patients with complicated UTI (paraplegia,
multiple sclerosis, or other compromised bladder
function; prostatic neoplasia, or indwelling catheters)
due to P. aeruginosa and to Pseudomonasflu 0 res-
censafter norfloxacin (800 mg daily) given for 5-10
days. However, follow-up cultures were not adequate
for all patients. In this study, one of three failures
occurred in a patient with a UTI caused by a resis-
tant strain of P. aeruginosa. Boerema and Van Saene
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[23] treated 16 similar patients with P. aeruginosa
UTI with norfloxacin (400-800 mg daily) for 3
months and reported a 75% cure rate, but three of
four failures were infections due to resistant strains
of P. aeruginosa. Sauerwein and Bauernfeind [73]
reported a 43% cure rate in 52 paraplegic patients
with recurrent UTI (due primarily to P. aeruginosa)
1 week after the end of a 10-day course of norfloxa-
cin (800 mg daily) and observed the emergence of
resistance in three (11010) of 28 P. aeruginosa strains
after therapy. Westenfelder et al. [74] treated 60 pa-
tients (14of whom were infected with P. aeruginosa)
with UTI and obstructions of the lower or upper uri-
nary tract, which in most patients were due to malig-
nancy, with norfloxacin (800 mg daily) for 7-9 days
and observed a bacteriologic cure rate of 91% after
5-9 days of therapy; in the P. aeruginosa infection
that did not respond to therapy, resistance developed.
Leigh et al. [39] reported a 63% cure rate in 27
UTI due to P. aeruginosa that were treated with
ciprofloxacin (400-500 mg daily) for 5 days in pa-
tients with abnormalities of the urinary tract and
reported development of resistance in three of 10
failures. Brown et al. [40] treated 16 patients with
chronic (>2 months duration) P. aeruginosa UTI
with ciprofloxacin (100-500 mg daily) for 2 weeks
and reported a 44% cure rate 8 weeks after the end
of treatment, observing emergence of resistance in
one case of failure. As a part of a comparative trial,
Williams and Griineberg [37] treated 18hospital in-
patients with P. aeruginosa UTI with ciprofloxacin
(200-500 mg daily) for 5 days, observing a cure rate
of 720/0 without emergence of resistance. Van Pop-
pel et al. [28] treated 29 patients with UTI (38% of
which were due to multiresistant P. aeruginosa) and
neurogenic bladder dysfunction with ciprofloxacin
(200 mg daily) for 7 days and reported a 48010 cure
rate after 1 week but only a 17% cure rate after 1
month; one P. aeruginosa strain developed resistance.
Using a higher dose regimen (1,000mg of ciproflox-
acin daily), Saavedra et al. [75] treated 28 patients
(20 with pseudomonal infections) with urinary tract
obstructions for a mean duration of 12 days, with
a cure rate at 4 weeks of 35%. A total of 26 patients
with UTI due to P. aeruginosa were treated with
ciprofloxacin (1,000mg daily) usually for 10days in
three open studies that included other infections [27,
29, 30]. Ninety-two percent of these patients were
cured, but the follow-up period was only 1 week.
Kumazawa et al. [31] treated 62 patients with com-
plicated UTI due to P. aeruginosa and observed bac-
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teriologic cure in 72.6070 after ciprofloxacin therapy
(400 mg daily for 5-14 days). Unfortunately, it is un-
clear when follow-up cultures were performed.
In conclusion, the patient's underlying conditions,
the dosages, and the durations of administration of
the fluoroquinolones varied considerably among
these studies, complicating a conclusive interpreta-
tion of the results. Nevertheless, the orally ad-
ministered fluoroquinolones have been effective
against urinary R aeruginosa infections, but emer-
gence of resistant strains was observed repeatedly.
Fluoroquinolones for the Treatment of Prostatitis
The results of treatment of bacterial prostatitis with
fluoroquinolones are summarized in table 4. Bolo-
gna et al. [76] treated 20 patients with chronic relaps-
ing prostatitis with a 10-day course of norfloxacin
(800 mg daily). Four weeks after the end of the treat-
ment, bacteriologic cure was observed in 85070 of the
patients. In a comparative study Sabbaj et al. [70]
treated 25 male patients with recurrent UTI and
culture-positive prostatic fluid or ejaculate with nor-
floxacin for 4-6 weeks and reported a 92% cure rate
at follow-up cultures at 1-3 weeks. Ciprofloxacin
(1,000mg daily) was tested by Guibert et al. [32] for
the treatment of 26 patients with acute (28-day treat-
ment) and chronic (84-day treatment) prostatitis due
primarily to E. coli. After 6 weeks,bacteriologic cure
had occurred in 77% of the patients. Suzuki et al.
[77] treated 22 patients (four with acute and 18with
chronic prostatitis) with ofloxacin (300-600 mg
daily) for 5-21 days. The segmented urine culture
technique was used, and an overall rate of bacterio-
logic cure of 82% was reported. All eight gram-
negative infections were eradicated, whereas only 10
of 14gram-positive coccal infections wereeradicated.
No follow-up cultures were performed in this study
after the end of the treatment. Finally, pefloxacin
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(800 mg daily) was given to 33 patients with acute
or recurrent prostatitis for a median duration of 28
days; the bacteriologic cure rate was 63070 in patients
followed up for up to 3 months (data on file, La-
boratoire Roger Bellon, Neuilly-sur-Seine, France).
Treatment of Patients with Renal Failure
The urinary recovery of fluoroquinolones decreases
as impairment of renal function progresses, but drug
concentrations may remain above the MIC for most
urinary pathogens [1, 78]. Thus, fluoroquinolone
treatment of UTI in patients with different levels of
renal failure is of special clinical interest. However,
the vast majority of controlled clinical trials have
excluded patients with impaired renal function. Only
a few clinical studies [39, 40, 47, 53] involved pa-
tients with renal failure. In one study [53], treatment
of UTI with enoxacin failed in three of five patients
with mild to severe renal failure (plasma creatinine
levels, 1.8-3.8 mg/loo mL) and structural abnormal-
ities of the urinary tract; it is notable that the three
failures occurred in patients with the highest creati-
nine levels. Brown et al. [40] described a failure in
a patient with chronic UTI due to R aeruginosa and
severe renal failure in whom concentrations of
ciprofloxacin in urine were similar (1 mg/L) to the
MIC for the organism. Schulz and Dorfler [47] ob-
served a 71% cure rate among 15patients with mild
to severerenal failure (plasma creatinine levels, 1.2-10
mg/l00 mL), and four patients undergoing hemodi-
alysis, whose doses of ofloxacin were adjusted
(100-400 mg daily). Two of the four patients receiv-
ing dialysis werecured, but one of these patients was
cured only after the dose of ofloxacin was doubled.
The therapeutic response was negatively affected by
concomitant treatment with antacids, which are
known to interfere with the gastrointestinal absorp-
tion of fluoroquinolones.
Table 4. Results of the treatment of bacterial prostatitis with fluoroquinolones.
No. of Dosage Duration Follow-up Bacteriologic
Agent patients (mg/day) (days) (weeks) cure rate (070) Reference
Norfloxacin 20 800 10 4 85 76
Norfloxacin 25 800 28-42 1-3 92 70
Ciprofloxacin 26 1,000 28/84 6 77 32
Ofloxacin 22 300-600 5-21 End of 82 77
treatment
Pefloxacin 33 800 28 12 63 *
* Data on file, Laboratoire Roger Bellon (Neuilly-sur-Seine, France).
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Conclusions
For the treatment of uncomplicated UTI, ran-
domized comparative trials of norfloxacin, cipro-
floxacin, and ofloxacin have conclusively shown
these drugs to be at least as effective as TMP-SMZ
and amoxicillin and usually superior to nalidixic
acid, pipemidic acid, and nitrofurantoin. In some
trials, however, the duration of treatment was >3
days, thus raising the question of whether such rela-
tively prolonged treatment was actually necessary-
considering that conventional short-term treatment
has been effective in such conditions.
Comparative trials of single-dose regimens have
been limited, and in two studies, treatment failures
have been attributed to the poor susceptibility of
gram-positive cocci such as S. saprophyticus after
single doses of norfloxacin or ciprofloxacin. Clearly,
the use of short-term treatment for uncomplicated
UTI requires careful, additional studies, but some
authors have questioned the interest of the sponsors
of such studies for the short-term approach in the
management of uncomplicated UTI [79].
For the treatment of complicated UTI, norfloxa-
cin, ciprofloxacin, and ofloxacin have demonstrated
good efficacy and were at least as effective as amox-
icillin and TMP-SMZ and were usually superior to
pipemidic acid. In these trials, however, the dura-
tion of treatment was relatively short when one con-
siders the necessity for prolonged administration of
antibiotics for complicated UTI.
The fewpublished reports of the outcome of clin-
ical trials of oral treatment of complicated UTI due
to R aeruginosa have indicated that the fluoroquino-
lones may be remarkably effective in this setting. Un-
fortunately, too many trials that include complicated
infections lack the data on follow-up 4-6 weeks af-
ter the end of the treatment that are critical in evalu-
ating efficacy. This follow-up period might be espe-
cially important when considering the possibility of
emergence of resistant organisms during fluoro-
quinolone treatment, as has been observed in other
clinical settings such as osteoarticular or pulmonary
infections.
The pharmacokinetic characteristics of fluoro-
quinolones suggest a possible role for the treatment
of chronic bacterial prostatitis [1]. Limited, noncom-
parative clinical trials suggest that the fluoroquino-
lones are effective in this condition. Clearly, careful
confirmatory clinical trials with microbiologically
well-documented infections and follow-up cultures
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for severalmonths after discontinuation of treatment
are urgently needed to conclusively establish a role
for the fluoroquinolones in the treatment of this
chronic condition.
The development of resistance to the fluoroquino-
lones might be related in part to the presence at the
infected site of concentrations of the antibiotic that
are barely inhibitory and that thus may permit the
growth of more resistant bacterial subpopulations.
Fluoroquinolones produce very high concentrations
of drug in the urine, and the emergence of resistance
in pathogens of the urinary tract during therapy with
fluoroquinolones has been observed only infre-
quently among organisms other than R aeruginosa.
However, preliminary data have indicated that emer-
gence of resistant R aeruginosa during fluoroquino-
lone therapy for complicated UTI might be a sig-
nificant problem.
Since the fluoroquinolones are excreted, in part,
by the kidney and their urinary recovery decreases
as renal function decreases, the treatment of UTI
in patients with renal failure should be investigated
carefully. The excellent activity of these compounds
in vitro and their lack of significant nephrotoxicity
make them potentially usable and safe in this set-
ting. However, at present only a few anecdotal
reports of the use of these agents in this setting are
available, and it is not possible to make a valid con-
clusion. Controlled trials involving patients with
different stages of renal failure are needed, and spe-
cial attention should be paid to the emergence of re-
sistance. Whether the widespread use of these agents
for the treatment of UTI will select resistant strains
at other body sites, as has been observed in some
French institutions after the widespread use of
pefloxacin, is uncertain [80].
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